RNA: SEC Form 8-K filed by Atrium Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for RNA
Across the 24 sessions after earlier RNA headlines, the stock closed higher 19 times and lower 4 times, with a median move of 1.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RNA | SPY |
|---|---|---|---|
| Oct 27, 2026 | Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome | +3.4% | +0.6% |
| Oct 22, 2026 | Roth Capital initiated coverage on Atrium Therapeutics with a new price target | +2.0% | -1.2% |
| Oct 21, 2026 | Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | +0.3% | +0.5% |
| Oct 20, 2026 | Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing | +4.9% | +0.3% |
| Oct 8, 2026 | Atrium Therapeutics Announces $50 Million Private Placement | +4.2% | -0.4% |
| Sep 22, 2026 | Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | +0.3% | -0.0% |
Quantisnow market dataNASDAQ
RNA
Atrium Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for RNA
Full RNA profile on Quantisnow Follow RNA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time